Humulin® R U-500 KwikPen® and EpiPen®/EpiPen Jr® approved for formulary addition

The Pharmacy Department’s Medication Use Policy team has been facilitating the implementation of Humulin® R U-500 KwikPen® and EpiPen/EpiPen Jr. to our formulary. The additions are expected to take place over the coming weeks.

Here’s what to expect:

Humulin® R U-500 KwikPen® Formulary Addition

  • Humulin® R U-500 KwikPen® was approved for formulary addition by our Pharmacy & Therapeutics Committee. It will only be available at the Chapel Hill campus at this time.
  • The medication is restricted to patients continuing home therapy and it requires an Endocrinology consult
  • It will be orderable via an Concentrated U-500 Insulin order panel in Epic®
  • An U-500 KwikPen® Clinical Guideline can be found at this Pharmacy Intranet page: http://pharmacy.intranet.unchealthcare.org/pharmacy/clinresources/clinguidelines
  • Go-live is anticipated for  July 6


EpiPen®/EpiPen Jr® Formulary Addition

  • EpiPen®/EpiPen Jr® was approved for formulary addition by our Pharmacy & Therapeutics Committee
  • We will be replacing epinephrine ampules with auto-injector pens (except for OR areas) at the Chapel Hill and Hillsborough Campuses
  • Go-live is anticipated for  July 11
Filed under: